Head to Head Review: BioLineRx (NASDAQ:BLRX) & Biomerica (NASDAQ:BMRA)

Biomerica (NASDAQ:BMRA – Get Free Report) and BioLineRx (NASDAQ:BLRX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.

Volatility & Risk

Biomerica has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Biomerica and BioLineRx, as provided by MarketBeat.com.

Biomerica presently has a consensus price target of $9.00, suggesting a potential upside of 467.82%. Given Biomerica’s higher possible upside, analysts clearly believe Biomerica is more favorable than BioLineRx.

Profitability

This table compares Biomerica and BioLineRx’s net margins, return on equity and return on assets.

Insider & Institutional Ownership

22.3% of Biomerica shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 18.0% of Biomerica shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Biomerica and BioLineRx”s top-line revenue, earnings per share and valuation.

BioLineRx has lower revenue, but higher earnings than Biomerica. Biomerica is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

About Biomerica

(Get Free Report)

Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.

About BioLineRx

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.